Press Releases on March 18, 2023

Global Report for Flame Retardant Cable Market Size is USD 41.89 billion

By 2030, the market for Flame Retardant Cable is projected to be worth USD 41.89 billion and grow at a CAGR of 23.9% from 2022 to 2030. LOS ANGELES, CALIFORNIA, USA, March 18, 2023 /⁨EINPresswire.com⁩/ -- Global Flame Retardant Cable Market Overview A …

Ukraine Focus Delivers First Shipment of Ambulances to Frontlines of War in Ukraine

With ambulance delivery, Ukraine Focus shows steadfast commitment to ensure that help is delivered directly to those Ukrainians who need it most WASHINGTON, DC, USA, March 18, 2023 /⁨EINPresswire.com⁩/ -- The American humanitarian relief organization …

Global Report on Colloidal Silica Market Size was Worth $930.00 Million in 2021 and will reach $1265.60 million in 2029

The market for Colloidal Silica was worth $930.00 million in 2021 and is expected to be worth $1265.60 million in 2029 thanks to a CAGR of 4.43%. LOS ANGELES, CALIFORNIA, USA, March 18, 2023 /⁨EINPresswire.com⁩/ -- Global Colloidal Silica Market …

Global Report on Market Size on Cylindrical Lithium Ion Battery will Increase from $8.40 Bn in 2021 to $9.80 Bn in 2029

The Cylindrical Lithium Ion Battery Market was $8.40 Billion USD in 2021 and is growing at a CAGR of 2.26% year on year, it will reach $9.80Billion USD in 2029. LOS ANGELES, CALIFORNIA, USA, March 18, 2023 /⁨EINPresswire.com⁩/ -- Global Cylindrical …

Global Report on Medical Oxygen Concentrators Market Size was $2.50 Bn USD in 2021 and will reach $3.50 Bn USD in 2029

Report on Medical Oxygen Concentrators increase from $2.50 Billion USD to $3.50 Billion USD in 2029 at a CAGR of 4.62%. LOS ANGELES, CALIFORNIA, USA, March 18, 2023 /⁨EINPresswire.com⁩/ -- Global Medical Oxygen Concentrators Market Overview Oxygen …

DuPont™ Liveo™ Healthcare exhibits at 2023 EBC Biopharma Conference and announces new Chinese brand name

Showcasing high-quality, high-performance healthcare products in China to meet growing local demand for biopharma processing solutions SHANGHAI, China (PRWEB) March 18, 2023 DuPont DD today starts its two-day exhibition at the 2023 EBC Biopharma Conference …

Welcome to the Future of Amazon Ads: Introducing AdRev.tech

AdRev.tech (AdRev) is proud to announce the launch of its Hybrid AI™ ad-tech platform, built to bring a managed service model to any size of advertising effort on Amazon. SEATTLE (PRWEB) March 18, 2023 AdRev.tech (AdRev) is proud to announce the launch of …

ALPHABET DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,...

NEW YORK, March 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alphabet Inc. ("Alphabet" or the "Company") GOOGL GOOG))) and reminds investors of the …

ACELYRIN, INC. Announces Izokibep Achieves HiSCR100 Responses at 12 Weeks in Moderate-to-Severe Hidradenitis Suppurativa

Data from the open label Part A of a Phase 2b/3 trial to be presented today at the American Academy of Dermatology (AAD) Annual Meeting At 12 weeks, participants achieved high orders of HiSCR (HiSCR75 and above), including 33% achieving HiSCR100 Izokibep …

3DuPont™ Liveo™ Healthcare exhibits at 2023 EBC Biopharma Conference and announces new Chinese brand name

Showcasing high-quality, high-performance healthcare products in China to meet growing local demand for biopharma processing solutions SHANGHAI, China, March 18, 2023 /PRNewswire-PRWeb/ -- DuPont DD today starts its two-day exhibition at the 2023 EBC …

Welcome to the Future of Amazon Ads: Introducing AdRev.tech

AdRev.tech (AdRev) is proud to announce the launch of its Hybrid AI™ ad-tech platform, built to bring a managed service model to any size of advertising effort on Amazon. SEATTLE, March 18, 2023 /PRNewswire-PRWeb/ -- AdRev.tech (AdRev) is proud to announce …

Press Release: Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-...

Dupixent® (dupilumab) late-breaking data at AAD show significant improvements in signs and symptoms of moderate-to-severe atopic hand and foot dermatitis More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo …

Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic ...

More than twice as many patients on Dupixent achieved clear or almost clear skin compared to placebo at 16 weeks Nearly four times as many patients on Dupixent saw a clinically meaningful reduction of itch, with improvements seen as early as one week …

AbbVie Announces Late-Breaking Results of Study Evaluating 52-Week Efficacy and Safety of SKYRIZI® (risankizumab) in Plaque ...

Treatment with SKYRIZI (risankizumab) demonstrated short- and long-term efficacy of psoriasis signs and symptoms (sPGA 0/1) at week 16 and week 52 in a difficult-to-treat population, with no new safety signals observed in an open-label, single-arm phase 3b …

CREDIT SUISSE CLASS ACTION ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Securities Class Action Lawsuit Filed ...

RADNOR, Pa., March 18, 2023 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey …

ROSEN, LEADING TRIAL ATTORNEYS, Encourages Charles River Laboratories International, Inc. Investors to Inquire About Securities ...

NEW YORK, March 18, 2023 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Charles River Laboratories International, Inc. CRL resulting from allegations …

Incyte Announces Long-Term Extension Data from Phase 3 TRuE-V Program Demonstrating Long-Term Safety and Durability of Response of ...

- Patients achieving a high level of facial repigmentation (≥F-VASI90) at Week 52 maintained durable response one year following withdrawal of treatment - Continued treatment with Opzelura for up to two years resulted in sustained facial repigmentation and …

Repair your home with help from USAGov

SUPER MICRO INVESTOR ALERT : Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $...

NEW YORK, March 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Super Micro Computer Inc.  ("Super Micro" or the "Company") SMCI. If you suffered …

MARATHON INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,...

NEW YORK, March 18, 2023 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Marathon Digital Holdings Inc. ("Marathon" or the "Company") MARA. If you suffered …